Comparison · NCT03192306-121489f6
Merlin vs Ethanol: Clinician Assessed Prevention of Progression to Classical Lesion
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Merlin vs Ethanol: Clinician Assessed Prevention of Progression to Classical Lesion. Trial comparisons, record NCT03192306-121489f6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03192306-121489f6
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.16 | 0.094 | 0.259 | wilson | |
| Risk in group 2 | 0.075 | 0.0348 | 0.154 | wilson | |
| Risk difference, group 1 minus group 2 | 0.085 | -0.0181 | 0.192 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.13 | 0.843 | 5.4 | log | |
| Odds ratio, group 1 over group 2 | 2.35 | 0.834 | 6.62 | log | |
| Number needed to treat, for one more participant with the outcome on Merlin than on Ethanol | 11.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Merlin | glycolic acid and ethanol mixture~Merlin: glycolic acid/ethanol solution | 12 | 75 | OG000 |
| Group 2 | Ethanol | Ethanol: Ethanol solution | 6 | 80 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Clinician Assessed Prevention of Progression to Classical Lesion
- Description
- Proportion of subjects in each treatment group who do not display classical lesions
- Time frame
- 14 days maximum
- Population
Subjects who developed a cold sore lesion and treated during the course of the trial. One subject in the Merlin cohort was lost to follow-up, did not complete the study and was therefore excluded from this analysis.
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for Episodic Treatment of Cold Sores
- NCT number
- NCT03192306
- Phases
- PHASE2
- Conditions
- Recurrent Herpes Labialis
- Interventions
- Merlin, Ethanol
- Lead sponsor
- Topical Remedy
- Results first posted
- 2018-08-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03192306?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03192306-121489f6